Analysts at Morgan Stanley (MS) are out with a report this morning upgrading shares of Google Inc. (GOOGL) with a ‘Overweight‘ from ‘Equal-Weight‘ rating. The search giant was also viewed positively at Argus. The firm sees Google’s Alphabet favorably and believes that shares are attractively valued given the company’s rapidly expanding businesses.
On valuation measures, Google Inc. Cl A shares are currently priced at 32.49x this year’s forecasted earnings compared to the industry’s 13.08x earnings multiple. Ticker has a forward P/E of 20.37 and t-12 price-to-sales ratio of 6.80. EPS for the same period is $21.22.
In the past 52 weeks, shares of Mountain, View California-based company have traded between a low of $490.91 and a high of $713.33 and are now at $689.50.
Shares are up 19.58% year-over-year and 30.08% year-to-date.
Oppenheimer analyst Shaul Eyal wrote in a note to investors today that CyberArk Software‘s (CYBR) momentum is strong and accelerating. He kept a $70 price target and ‘Outperform’ rating on the shares. CYBR last night reported stronger than expected 2Q’15 results and raised its fiscal year guidance.
The Israeli IT security firm handed in earnings of $0.19 per share on revenue of $36.4 million, beating Wall Street estimates of $0.06 per share on revenue of $32.34 million.
For the current quarter ending in October, CYBR provided EPS guidance of $0.11 – $0.13 versus consensus of $0.08 per share. The company also issued revenue projection of $36 – $37 million, compared to the consensus revenue estimate of $34.30 million. Full-year EPS is expected in the range of $0.62 to $0.65 per share, with revs ranging from $145 to $147 million.
CyberArk shares have gained nearly 49% since the beginning of the year.
Inogen, Inc. (INGN) was reiterated a ‘Buy’ by Stifel analysts on Wednesday. The broker also raised its price target on the stock to $48 from $45.
INGN is up $5.96 at $48.56 on heavy volume. Midway through trading Wednesday, 600K shares of Inogen Inc. have exchanged hands as compared to its average daily volume of 230K shares. The stock has ranged in a price between $45.19-$50.98 after having opened the day at $45.74 as compared to the previous trading day’s close of $42.60.
In the past 52 weeks, shares of Goleta, Calif.-based medical technology firm have traded between a low of $18.50 and a high of $50.98.
Shares are up 131.90% year-over-year and 35.80% year-to-date.
Abiomed, Inc. (ABMD) was reiterated as ‘Buy’ with a $129 from $96 price target on Wednesday by The Benchmark Company.
ABMD is currently printing a higher than average trading volume with the issue trading 862K shares, compared to the average daily volume of 825k. The stock began trading this morning at $100 to currently trade 0.60% lower from the prior days close of $100.95. On an intraday basis it has gotten as low as $98.03 and as high as $102.15.
ABMD shares have advanced 48.65% in the last 4 weeks and 47.24% in the past three months. Over the past 5 trading sessions the stock has gained 13.68%.
The Danvers, Massachusetts-based company, which is currently valued at $4.22 billion, has a median Street price target of $96 with a high target of $108.
Abiomed Inc. is up 293.26% year-over-year, compared with a 7.06% gain in the S&P 500.